Back to top
more

Agenus (AGEN)

(Real Time Quote from BATS)

$5.00 USD

5.00
157,422

-0.13 (-2.53%)

Updated Aug 13, 2024 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agenus Stock Up on Licensing Deal With China-Based Firm

by Zacks Equity Research

Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.

Why Is Agenus (AGEN) Up 51.6% Since Last Earnings Report?

by Zacks Equity Research

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%

by Zacks Equity Research

Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AGEN) Outperforming Other Medical Stocks This Year?

Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

Protalix Submits BLA for Fabry Disease Candidate PRX-102

by Zacks Equity Research

Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.

Mersana Stock Spikes on Interim Data on Cancer Candidate

by Zacks Equity Research

Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.

Ironwood to Halt MD-7246 Development After Study Failure

by Zacks Equity Research

Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.

Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance

by Zacks Equity Research

The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.

Agenus (AGEN): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

Agenus (AGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Agenus (AGEN) Upgraded to Buy: Here's Why

by Zacks Equity Research

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 11.43% and 22.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agenus' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Agenus.

Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

Why Agenus (AGEN) Stock Might be a Great Pick

by Zacks Equity Research

Agenus (AGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Agenus (AGEN) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Agenus (AGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Agenus (AGEN) betters loss estimates and also beats on sales in the fourth quarter. The company gets a Fast Track tag for balstilimab & zalifrelimab combo to address the second-line cervical cancer.

Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 46.34% and 102.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Agenus (AGEN) Q4 Earnings Expected to Decline

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Immunomedics (IMMU) Reports Wider-Than-Expected Q4 Loss

by Zacks Equity Research

Immunomedics (IMMU) posts wider-than-expected Q4 loss. Its BLA seeking accelerated approval for sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) is accepted for filing by FDA.

ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales

by Zacks Equity Research

ACADIA (ACAD) beats on earnings and revenues in the fourth quarter.

Gilead Sciences (GILD) Surges: Stock Moves 6.6% Higher

by Zacks Equity Research

Gilead Sciences (GILD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Global Blood (GBT) Q4 Earnings Miss, Voxelotor Gets FDA Nod

by Zacks Equity Research

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2019. The FDA approves voxelotor (Oxbryta) for the treatment of SCD in adults, and children 12 years of age and older.

Horizon Therapeutics' (HZNP) Q4 Earnings Beat Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) beat earnings and sales estimates in the fourth quarter of 2019.